| Biomarker ID | 505 |
| PMID | 20035634 |
| Year | 2009 |
| Biomarker | MAP3K5 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Gleason Score 8-10 |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include:- Differentiation pathway in PC12 cells,T cell signal transduction,G alpha s pathway, Neurotrophin signaling pathway, TNF-alpha signaling pathway |
| Experiment | Gleason Score 6 Vs Gleason Score (8-10) |
| Type of Biomarker | Prognostic |
| Cohort | 65 RNA samples derived from 13 benign and 52 prostate cancer tissue comprising 25 samples with Gleason Score (GS) 6 and 27 samples with GS 8-10 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | qRT-PCR: p=0.0129 |
| Method Used | qRT-PCR and Immunohistochemistry |
| Clinical | No |
| Remarks | Another 2500 differentially expressed genes between prostate cancer and benign samples are available from supplementry material of the paper |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | MAP3K5 |